Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Rosalind Franklin Institute and the University of Oxford’s Department of Pharmacology have entered into a strategic partnership for Next Generation Chemistry.

Pictured left to right are Professor Ben Davis, Professor Frances Platt, Lord Chris Patten, Professor James Naismith and Dr Paul McCubbin celebrate this strategic partnership. Photo credit: Stuart March
(l-r): Professor Ben Davis, Professor Frances Platt, Lord Chris Patten, Professor James Naismith and Dr Paul McCubbin celebrate this strategic partnership. Photo credit: Stuart March

Formed around the lab of Professor Ben Davis, Director of Next Generation Chemistry at The Franklin, the partnership will see bilateral movement of researchers between the Franklin and Oxford, widening access to the cutting edge facilities at Harwell.

Professor Frances Platt, Head of Department at the University of Oxford Department of Pharmacology said, “I am delighted that Professor Davis will be joining our department – his research is an excellent fit with existing work taking place in Pharmacology. This partnership with The Franklin offers a wealth of opportunity for our research and academic staff to form exciting new collaborations with world-leading scientists and facilities.”

One of the key aims for the Davis group is to perform ‘in-cell chemistry’ – editing proteins and other biomolecules within the cell for therapeutic or diagnostic purposes. This work is revolutionary in its approach, and is highly complementary to other Franklin themes, including mass spectrometry imaging, structural biology, and correlated imaging.

Professor Davis said “This collaboration means a huge amount to my group, who will be able to carry out their work in two of the best places to explore the chemistry of life in the country. We are all incredibly excited to get started and have felt very welcomed. ”

Recent collaborative publications from the Davis group include work on borylation of proteins – introducing new function via the element boron to proteins, as well as the light-mediated editing of proteins to change their primary sequence without the need for classical genetic or other ‘gene-editing’ approaches.

Other current work is trying to understand the role that interaction with host (human) sugars may have played in the function of the SARS-CoV-2 virus. In 2021, an international collaboration including the Davis group also uncovered the role of LanCL proteins, by using protein editing amongst other methods to solve a 20 year mystery of their function and pointing to a new pathway of protein repair that may be present in many higher organisms.

 

Similar stories

Anthony group research offers new treatment hope for ALS patients

New research, led by the Anthony Group in Pharmacology and funded by GeNeuro, suggests a pathway to a new precision medicine approach for patients with amyotrophic lateral sclerosis (ALS). The groundbreaking findings were presented at the 35th International Symposium on ALS/MND, which took place in Montreal, Canada, from 6-8 December 2024.